Phase II Trial of Temodar [temozolomide] Plus O6-Benzylguanine [benzylguanine] (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2012
At a glance
- Drugs Benzylguanine (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Jan 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 22 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.